Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)

NCT03264547 is registered in ClinicalTrials.gov with Japan Breast Cancer Research Group as lead sponsor.

NCT NCT03264547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03264547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
Lead sponsor
Japan Breast Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2017
Completion date
December 31, 2024
Enrollment
446 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer